RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

DENVER, Oct. 17, 2024 /PRNewswire/ -- Colorado State University Global (CSU Global) has selected Dr. Audra Spicer to serve as ...

The vaccine began being administered through the public health sysem in February this year. It was prioritized for children ...

Dr. Sheikh holds dual responsibilities at Takeda as the Head of Global Development for all therapeutic areas - ...

This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...

Wave Life Sciences (WVE) said Takeda (TAK) has elected not to exercise its option to further develop its Huntington’s disease ...